Related Experiment Video
Updated: Oct 7, 2025

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
Interpreting Patient-Reported Outcome Scores: Pediatric Inflammatory Bowel Disease as a Use Case
Julia Schuchard1, Adam C Carle2, Michael D Kappelman3
1Department of Pediatrics, Children's Hospital of Philadelphia (J Schuchard and CB Forrest), Philadelphia, Pa.
Insights
This study provides methods to interpret Patient-Reported Outcomes Measurement Information System (PROMIS) scores for pediatric inflammatory bowel disease (IBD) patients. It establishes IBD-specific percentiles and minimal clinically important differences for better score interpretation.
Area of Science:
- Pediatric gastroenterology
- Clinical trial methodology
- Health outcomes research
Background:
- Interpreting patient-reported outcome measure (PROM) scores in pediatric inflammatory bowel disease (IBD) is crucial for clinical decision-making.
- Existing interpretation methods may not adequately capture the nuances of health in pediatric IBD populations.
Purpose of the Study:
- To establish disease-specific percentiles and minimal clinically important difference (MCID) thresholds for 6 pediatric PROMIS measures in patients with IBD.
- To demonstrate the application of these interpretation tools using data from a clinical trial.
Main Methods:
- A prospective cohort study of 1049 patients (ages 8-23) with IBD was used to establish IBD-specific percentiles and MCID for 6 PROMIS measures.
- These measures, along with general population percentiles and reliable change index, were applied to interpret PROM scores in a clinical trial sample (n=294, ages 8-20) at baseline and 3 months.
Main Results:
- At baseline, the clinical trial sample reported worse health than the general population (e.g., 22% above 95th percentile for Fatigue).
- Compared to a reference IBD sample, the clinical trial sample showed slightly worse scores (e.g., 8% above 95th percentile for Fatigue).
- MCID application showed that among patients with improved Pediatric Crohn's Disease Activity Index scores, significant proportions also improved in IBD Symptoms (45%), Fatigue (47%), and Pain Interference (65%).
Conclusions:
- This study successfully established IBD-specific percentiles for 6 pediatric PROMIS measures.
- The findings demonstrate the utility of these percentiles and MCID for interpreting PROM scores in pediatric IBD clinical trials.
- These tools enhance the understanding of patient-reported outcomes in this population.
Objective:
To demonstrate how to interpret Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric patient-reported outcome measure (PROM) scores for patients with pediatric inflammatory bowel disease (IBD).
Methods:
Using data from a prospective cohort study of patients ages 8 to 23 years with IBD (n = 1049), we established disease-specific percentiles and computed the minimal clinically important difference (MCID) change score for 6 pediatric PROMs. We applied these results, general population percentiles, and the reliable change index to interpret PROM scores in a clinical trial sample of patients ages 8 to 20 years with IBD (n = 294) in which PROMIS PROMs were obtained at baseline and 3 months later.
Results:
Application of general population percentiles showed that the clinical trial sample at baseline had moderately worse self-reported health than the general population (22% of patients at or above the 95th percentile on Fatigue; 21% on Pain Interference). IBD-specific percentiles showed that the sample was somewhat worse than the reference IBD sample (8% of patients at or above the 95th percentile on Fatigue; 11% on Pain Interference). Application of the MCID threshold indicated that among the subgroup of patients that improved by 15 or more on the short Pediatric Crohn's Disease Activity Index (n = 38), 45% also improved on IBD Symptoms, 47% for Fatigue, and 65% for Pain Interference.
Conclusion:
This study established IBD-specific percentiles for 6 pediatric PROMIS measures and demonstrated the application of percentiles and other methods for interpreting PROM scores.
More Related Videos
15:49Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
02:28Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...